Cambridge Investment Research Advisors Inc. increased its holdings in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 3.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,130 shares of the biopharmaceutical company’s stock after acquiring an additional 800 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Achillion Pharmaceuticals were worth $106,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in ACHN. Vanguard Group Inc. raised its stake in shares of Achillion Pharmaceuticals by 7.2% during the 1st quarter. Vanguard Group Inc. now owns 9,585,823 shares of the biopharmaceutical company’s stock worth $40,357,000 after purchasing an additional 646,415 shares in the last quarter. Eventide Asset Management LLC purchased a new stake in shares of Achillion Pharmaceuticals during the 1st quarter worth about $2,526,000. Stifel Financial Corp purchased a new stake in shares of Achillion Pharmaceuticals during the 1st quarter worth about $1,744,000. Teachers Advisors LLC raised its stake in shares of Achillion Pharmaceuticals by 42.9% during the 1st quarter. Teachers Advisors LLC now owns 1,347,858 shares of the biopharmaceutical company’s stock worth $5,674,000 after purchasing an additional 404,317 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Achillion Pharmaceuticals by 51.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 613,006 shares of the biopharmaceutical company’s stock worth $2,581,000 after purchasing an additional 207,204 shares in the last quarter. 74.11% of the stock is owned by hedge funds and other institutional investors.

Achillion Pharmaceuticals, Inc. (ACHN) opened at 4.11 on Friday. The company’s market capitalization is $562.09 million. The company has a 50 day moving average price of $4.48 and a 200-day moving average price of $4.20. Achillion Pharmaceuticals, Inc. has a 52 week low of $3.15 and a 52 week high of $9.19.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). During the same period in the prior year, the business posted ($0.14) earnings per share. On average, equities analysts anticipate that Achillion Pharmaceuticals, Inc. will post ($0.66) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/24/achillion-pharmaceuticals-inc-achn-shares-bought-by-cambridge-investment-research-advisors-inc.html.

A number of research firms have recently weighed in on ACHN. BidaskClub raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Maxim Group set a $7.00 price target on Achillion Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Robert W. Baird downgraded Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target for the company. in a research note on Thursday, August 10th. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Chardan Capital cut their price target on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $6.50.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.